Sanofi (Ablynx)

Technologiepark 21
9052 Zwijnaarde
BE
Sanofi (Ablynx)
Foundation date
13/07/2001
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Cardiovascular
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the nervous system
- #Infectious and parasitic diseases
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
Sanofi R&D Belgium based in Ghent is as an end-to-end research and early development Center of Excellence and active in the discovery of NANOBODY® molecules, through the development of drugs up to their clinical proof-of-concept.
NANOBODY® molecules are proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® technology is the next generation of antibody-derived biologics and have great potential. They are being developed for the treatment of a range of serious and life-threatening human diseases including hematology, inflammation, immune-oncology, oncology and rare diseases.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
2206 '23
Translational Research in Crops
Event by: VIB
Latest news
More news-
Mithra appoints experienced life sciences executive Christian Homsy* as Chairman
10 hours ago
Read more
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
How garbage disposal clogs in cells can lead to Alzheimer’s
Friday May 26th 2023
Read more
Jobs
More jobs-
30/05/23
Remote, Brussels, Abroad
Executive, Chief Financial Officer - European Operations
Permanent, Freelance
General Inception -
-